Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Status:
Recruiting
Trial end date:
2025-08-15
Target enrollment:
Participant gender:
Summary
This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in
RAS pathway activated CMML.
All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib
will be administered for three weeks followed by a one week break prior to the start of the
following cycle. Patients will remain on study therapy until treatment discontinuation
criteria is met.